<bill session="107" type="h" number="1185" updated="2013-07-14T18:57:23-04:00">
  <state datetime="2001-03-22">REFERRED</state>
  <status>
    <introduced datetime="2001-03-22"/>
  </status>
  <introduced datetime="2001-03-22"/>
  <titles>
    <title as="introduced" type="short">Global Access to HIV/AIDS Medicines Act of 2001</title>
    <title as="introduced" type="official">To prohibit through negotiation or otherwise the revocation or revision of any intellectual property or competition law or policy of a developing country, including any sub-Saharan African country, that regulates HIV/AIDS pharmaceuticals or medical technologies, and for other purposes.</title>
  </titles>
  <sponsor id="400237"/>
  <cosponsors>
    <cosponsor id="400013" joined="2001-05-09"/>
    <cosponsor id="400067" joined="2001-05-09"/>
    <cosponsor id="400073" joined="2001-03-22"/>
    <cosponsor id="400075" joined="2001-05-02"/>
    <cosponsor id="400080" joined="2001-05-02"/>
    <cosponsor id="400090" joined="2001-06-12"/>
    <cosponsor id="400093" joined="2001-03-22"/>
    <cosponsor id="400199" joined="2001-03-22"/>
    <cosponsor id="400208" joined="2001-03-22"/>
    <cosponsor id="400217" joined="2001-03-22"/>
    <cosponsor id="400275" joined="2001-03-22"/>
    <cosponsor id="400295" joined="2001-06-28"/>
    <cosponsor id="400306" joined="2001-05-23"/>
    <cosponsor id="400357" joined="2001-03-22"/>
    <cosponsor id="400360" joined="2001-03-22"/>
    <cosponsor id="400422" joined="2001-04-04"/>
    <cosponsor id="400438" joined="2001-05-02"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2001-03-22">
      <text>Referred to the House Committee on International Relations.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSFA" name="House International Relations" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="International affairs"/>
    <term name="AIDS (Disease)"/>
    <term name="Access to health care"/>
    <term name="Africa (Sub-Saharan)"/>
    <term name="Appropriations"/>
    <term name="Commerce"/>
    <term name="Developing countries"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Economics and public finance"/>
    <term name="Epidemics"/>
    <term name="Foreign trade and international finance"/>
    <term name="Generic drugs"/>
    <term name="Health"/>
    <term name="Human immunodeficiency viruses"/>
    <term name="Intellectual property"/>
    <term name="Medical research"/>
    <term name="Medical technology"/>
    <term name="Patent agreements"/>
    <term name="Patent infringement"/>
    <term name="Patents"/>
    <term name="Pharmaceutical research"/>
    <term name="Preventive medicine"/>
    <term name="Public health"/>
    <term name="Science, technology, communications"/>
    <term name="Trade agreements"/>
    <term name="Trade negotiations"/>
    <term name="Vaccines"/>
  </subjects>
  <amendments/>
  <summary>3/22/2001--Introduced.
Global Access to HIV/AIDS Medicines Act of 2001 - Prohibits funds appropriated to U.S. Federal agencies from being expended to seek, through negotiation or otherwise, the revocation or revision of intellectual property law or policy of a developing country that regulates HIV/AIDS pharmaceuticals or medical technologies, if such law or policy: (1) promotes access to HIV/AIDS pharmaceuticals or medical technologies to the country's population; and (2) provides adequate and effective intellectual property protection consistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights of the Uruguay Round Agreements Act. Includes among such developing countries any sub-Saharan African country five percent or more of whose population is infected with HIV, or whose government has declared a national emergency with respect to HIV/AIDS.Encourages such developing countries to implement policies designed to address the underlying causes of the HIV/AIDS crisis by making efforts to encourage practices that will prevent further transmission and infection and to stimulate development of the infrastructure necessary to deliver adequate health services, including policies that provide an incentive for public and private research on, and development of, vaccines and other medical innovations that will combat the HIV/AIDS epidemic, particularly in Africa.</summary>
</bill>
